Free Trial
→ Stop picking AI winners. Start collecting every Thursday (From Investors Alley) (Ad)tc pixel Free KOD Stock Alerts

Kodiak Sciences (KOD) Financials

Kodiak Sciences logo
$86.85 -1.27 (-1.45%)
As of 09:30 AM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare
Annual Income Statements for Kodiak Sciences

Annual Income Statements for Kodiak Sciences

This table shows Kodiak Sciences' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -17 -53 -68 -47 -133 -267 -334 -260 -176 -230
Consolidated Net Income / (Loss)		 -17 -28 -41 -47 -133 -267 -334 -260 -176 -230
Net Income / (Loss) Continuing Operations		 -17 -53 -68 -47 -133 -267 -334 -260 -176 -230
Total Pre-Tax Income 		-17 -53 -62 -47 -133 -267 -334 -260 -176 -230
Total Operating Income		 -17 -26 -26 -49 -136 -267 -341 -277 -187 -234
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 17 51 53 49 136 267 341 277 187 234
Selling, General & Admin Expense		 3.10 3.50 7.58 12 29 50 74 71 61 52
Research & Development Expense		 14 22 19 38 107 217 268 206 126 182
Total Other Income / (Expense), net		 0.02 -2.42 -9.59 1.83 2.91 0.06 7.56 17 11 4.42
Interest Expense		 0.01 1.19 5.52 0.01 0.03 0.05 0.02 0.01 0.00 0.00
Interest & Investment Income		 - 0.03 0.62 1.57 2.97 0.30 7.07 17 11 4.52
Other Income / (Expense), net		 0.03 -1.26 -4.69 0.27 -0.03 -0.19 0.50 0.11 -0.51 -0.10
Basic Earnings per Share		 ($2.38) ($3.72) ($2.77) ($1.25) ($2.91) ($5.16) ($6.39) ($4.97) ($3.35) ($4.32)
Weighted Average Basic Shares Outstanding		 7.21M 7.52M 14.98M 37.85M 45.74M 51.79M 52.25M 52.41M 52.58M 53.21M
Diluted Earnings per Share		 ($2.38) ($3.72) ($2.77) ($1.25) ($2.91) ($5.16) ($6.39) ($4.97) ($3.35) ($4.32)
Weighted Average Diluted Shares Outstanding		 7.21M 7.52M 14.98M 37.85M 45.74M 51.79M 52.25M 52.41M 52.58M 53.21M
Weighted Average Basic & Diluted Shares Outstanding		 7.21M 7.52M 14.98M 37.85M 45.74M 51.79M 52.34M 52.51M 52.75M 61.85M

Quarterly Income Statements for Kodiak Sciences

This table shows Kodiak Sciences' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Income / (Loss) Attributable to Common Shareholders		 -60 -43 -45 -44 -44 -57 -54 -61 -57 -58 -66
Consolidated Net Income / (Loss)		 -60 -43 -45 -44 -44 -57 -54 -61 -57 -58 -66
Net Income / (Loss) Continuing Operations		 -60 -43 -45 -44 -44 -57 -54 -61 -57 -58 -66
Total Pre-Tax Income 		-60 -43 -45 -44 -44 -57 -54 -61 -57 -58 -66
Total Operating Income		 -63 -46 -48 -47 -46 -59 -56 -62 -57 -60 -67
Total Gross Profit		 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Total Revenue		 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Total Cost of Revenue		 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Total Operating Expenses		 63 46 48 47 46 59 56 62 57 60 67
Selling, General & Admin Expense		 17 16 15 15 14 15 13 12 12 11 11
Research & Development Expense		 47 30 33 32 32 44 43 50 45 49 56
Total Other Income / (Expense), net		 3.86 3.02 2.87 2.69 2.07 1.61 1.20 0.90 0.72 1.62 1.20
Interest & Investment Income		 3.90 3.35 2.95 2.71 2.13 1.60 1.24 0.92 0.76 1.64 1.26
Other Income / (Expense), net		 -0.04 -0.34 -0.09 -0.03 -0.06 0.01 -0.04 -0.02 -0.04 -0.02 -0.06
Basic Earnings per Share		 ($1.14) ($0.82) ($0.86) ($0.84) ($0.83) ($1.09) ($1.03) ($1.16) ($1.04) ($0.94) ($1.05)
Weighted Average Basic Shares Outstanding		 52.41M 52.51M 52.55M 52.62M 52.58M 52.75M 52.78M 52.86M 53.21M 61.86M 62.63M
Diluted Earnings per Share		 ($1.14) ($0.82) ($0.86) ($0.84) ($0.83) ($1.09) ($1.03) ($1.16) ($1.04) ($0.94) ($1.05)
Weighted Average Diluted Shares Outstanding		 52.41M 52.51M 52.55M 52.62M 52.58M 52.75M 52.78M 52.86M 53.21M 61.86M 62.63M
Weighted Average Basic & Diluted Shares Outstanding		 52.51M 52.53M 52.61M 52.62M 52.75M 52.76M 52.82M 53.05M 61.85M 62.58M 62.85M

Annual Cash Flow Statements for Kodiak Sciences

This table details how cash moves in and out of Kodiak Sciences' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -17 -8.23 87 124 739 -213 -541 95 -118 42
Net Cash From Operating Activities		 -16 -18 -29 -39 -83 -182 -206 -154 -117 -136
Net Cash From Continuing Operating Activities		 -16 -18 -29 -39 -83 -182 -206 -154 -117 -136
Net Income / (Loss) Continuing Operations		 -17 -28 -41 -47 -133 -267 -334 -260 -176 -230
Consolidated Net Income / (Loss)		 -17 -28 -41 -47 -133 -267 -334 -260 -176 -230
Depreciation Expense		 0.26 0.55 0.49 0.54 0.48 1.00 3.80 18 19 18
Amortization Expense		 0.00 1.16 5.48 0.13 3.73 7.79 6.19 6.80 8.00 7.99
Non-Cash Adjustments To Reconcile Net Income		 0.27 1.54 13 6.11 31 62 105 89 61 62
Changes in Operating Assets and Liabilities, net		 0.56 7.04 -6.39 1.44 15 14 12 -7.35 -28 5.37
Net Cash From Investing Activities		 -0.77 -0.21 -0.58 -137 105 -39 -337 249 -0.76 -0.51
Net Cash From Continuing Investing Activities		 -0.77 -0.21 -0.58 -137 105 -39 -337 249 -0.76 -0.51
Purchase of Property, Plant & Equipment		 -0.77 -0.21 -0.08 -0.44 -3.81 -17 -37 -41 -0.38 -0.51
Purchase of Investments		 - 0.00 0.00 -151 -86 0.00 -428 -49 0.00 0.00
Sale and/or Maturity of Investments		 - 0.00 0.00 14 198 25 138 340 0.00 0.00
Other Investing Activities, net		 0.00 0.00 -0.50 0.00 -3.18 -46 -9.73 -0.08 -0.38 0.00
Net Cash From Financing Activities		 -0.12 9.64 116 300 717 8.18 1.90 0.03 0.50 178
Net Cash From Continuing Financing Activities		 -0.12 9.64 116 300 717 8.18 1.90 0.03 0.50 178
Issuance of Common Equity		 0.00 0.00 84 298 612 0.48 0.17 0.18 0.11 173
Other Financing Activities, net		 -0.05 -0.09 -0.04 2.12 5.72 7.70 1.72 -0.15 0.39 5.16
Cash Interest Paid		 0.01 0.02 0.02 0.01 0.03 0.02 0.02 0.01 0.00 0.00

Quarterly Cash Flow Statements for Kodiak Sciences

This table details how cash moves in and out of Kodiak Sciences' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Change in Cash & Equivalents		 -60 -40 -27 -21 -30 -29 -35 -32 138 -40 -44
Net Cash From Operating Activities		 -32 -40 -26 -21 -30 -29 -35 -33 -39 -40 -46
Net Cash From Continuing Operating Activities		 -32 -40 -26 -21 -30 -29 -35 -33 -39 -40 -46
Net Income / (Loss) Continuing Operations		 -60 -43 -45 -44 -44 -57 -54 -61 -57 -58 -66
Consolidated Net Income / (Loss)		 -60 -43 -45 -44 -44 -57 -54 -61 -57 -58 -66
Depreciation Expense		 4.73 4.70 4.70 4.69 4.63 4.60 4.59 4.59 4.54 4.11 4.11
Amortization Expense		 1.93 1.94 1.99 2.01 2.06 2.13 1.94 1.95 1.97 2.23 2.08
Non-Cash Adjustments To Reconcile Net Income		 23 19 19 15 8.62 18 16 14 13 12 12
Changes in Operating Assets and Liabilities, net		 -2.53 -22 -6.64 1.28 -1.27 3.85 -2.54 7.99 -2.43 -0.35 1.61
Net Cash From Investing Activities		 -28 -0.17 -0.26 -0.21 -0.12 -0.27 -0.13 -0.06 -0.04 -0.94 -0.35
Net Cash From Continuing Investing Activities		 -28 -0.17 -0.26 -0.21 -0.12 -0.27 -0.13 -0.06 -0.04 -0.94 -0.35
Purchase of Property, Plant & Equipment		 -27 -0.02 -0.05 -0.18 -0.12 -0.27 -0.13 -0.06 -0.04 -0.94 -0.35
Net Cash From Financing Activities		 -0.12 0.04 0.06 - 0.40 0.12 0.12 0.81 177 0.62 2.96
Net Cash From Continuing Financing Activities		 -0.12 0.04 0.06 - 0.40 0.12 0.12 0.81 177 0.62 2.96
Other Financing Activities, net		 -0.18 0.04 - - 0.36 0.12 0.04 0.81 4.19 0.62 2.86

Annual Balance Sheets for Kodiak Sciences

This table presents Kodiak Sciences' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 3.24 92 359 1,067 904 667 479 336 352
Total Current Assets		 1.60 90 339 972 735 486 289 172 215
Cash & Equivalents		 1.40 88 212 944 732 190 286 168 210
Prepaid Expenses		 0.20 2.20 2.75 3.03 3.30 7.07 3.80 3.86 4.95
Plant, Property, & Equipment, net		 1.51 1.10 1.00 5.14 41 56 120 102 85
Total Noncurrent Assets		 0.14 0.64 19 90 128 124 70 61 51
Other Noncurrent Operating Assets		 0.14 0.64 6.94 90 128 124 70 61 51
Total Liabilities & Shareholders' Equity		 3.24 92 359 1,067 904 667 479 336 352
Total Liabilities		 22 5.36 14 207 241 230 214 185 194
Total Current Liabilities		 9.16 4.83 12 31 65 52 42 26 46
Accounts Payable		 3.36 1.05 2.62 8.65 12 9.13 14 3.92 13
Accrued Expenses		 5.80 3.78 8.66 20 48 33 18 11 21
Other Current Liabilities		 - 0.00 0.43 2.37 3.93 9.93 9.77 11 12
Total Noncurrent Liabilities		 13 0.53 1.80 175 176 178 172 160 149
Other Noncurrent Operating Liabilities		 2.89 0.53 1.80 175 176 178 172 160 149
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -69 87 345 861 663 436 266 150 157
Total Preferred & Common Equity		 -69 87 345 861 663 436 266 150 157
Preferred Stock		 - 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -69 87 345 861 663 436 266 150 157
Common Stock		 0.59 198 503 1,152 1,222 1,330 1,418 1,479 1,716
Retained Earnings		 -69 -111 -158 -291 -558 -892 -1,153 -1,329 -1,559

Quarterly Balance Sheets for Kodiak Sciences

This table presents Kodiak Sciences' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026
Period end date 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026
Total Assets		 590 548 435 402 373 298 257 218 306 257
Total Current Assets		 387 351 252 225 202 143 108 76 175 131
Cash & Equivalents		 379 346 246 219 198 139 104 72 170 126
Prepaid Expenses		 8.29 5.26 5.59 5.40 4.63 3.83 3.75 3.69 5.73 5.46
Plant, Property, & Equipment, net		 130 125 116 111 107 98 93 89 82 78
Total Noncurrent Assets		 73 72 67 66 63 57 55 53 49 47
Other Noncurrent Operating Assets		 73 72 67 66 63 57 55 53 49 47
Total Liabilities & Shareholders' Equity		 590 548 435 402 373 298 257 218 306 257
Total Liabilities		 251 245 194 187 187 189 186 194 194 196
Total Current Liabilities		 74 71 25 21 24 31 31 42 50 53
Accounts Payable		 12 39 2.49 1.87 3.29 6.54 5.06 10 11 13
Accrued Expenses		 54 23 13 9.44 11 13 15 20 27 30
Other Current Liabilities		 7.85 9.02 9.61 9.89 10 11 11 12 12 9.81
Total Noncurrent Liabilities		 177 174 169 166 163 157 155 152 144 143
Other Noncurrent Operating Liabilities		 177 174 169 166 163 157 155 152 144 143
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 338 302 241 215 185 109 70 24 112 61
Total Preferred & Common Equity		 338 302 241 215 185 109 70 24 112 61
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 338 302 241 215 185 109 70 24 112 61
Common Stock		 1,381 1,395 1,437 1,455 1,470 1,495 1,511 1,526 1,729 1,744
Retained Earnings		 -1,043 -1,093 -1,196 -1,241 -1,285 -1,386 -1,441 -1,502 -1,617 -1,683

Annual Metrics And Ratios for Kodiak Sciences

This table displays calculated financial ratios and metrics derived from Kodiak Sciences' official financial filings.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 0.00 36,829,857.00 37,058,168.00 44,803,447.00 51,717,286.00 52,309,154.00 52,472,291.00 - 53,048,428.00
DEI Adjusted Shares Outstanding		 0.00 0.00 36,829,857.00 37,058,168.00 44,803,447.00 51,717,286.00 52,309,154.00 52,472,291.00 - 53,048,428.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 0.00 -1.84 -1.28 -2.97 -5.16 -6.38 -4.96 - -4.34
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 0.00% -48.62% -0.08% -92.33% -173.20% -96.05% -28.03% 23.81% 36.28% -29.58%
EBIT Growth		 0.00% -56.37% -15.99% -57.51% -178.05% -96.45% -27.55% 18.68% 32.41% -25.15%
NOPAT Growth		 0.00% -48.80% -3.34% -86.51% -176.49% -96.35% -27.83% 18.76% 32.62% -25.44%
Net Income Growth		 0.00% -63.06% -48.35% -14.29% -181.00% -100.60% -25.03% 21.97% 32.36% -30.51%
EPS Growth		 0.00% -56.30% 25.54% 54.87% -132.80% -77.32% -23.84% 22.22% 32.60% -28.96%
Operating Cash Flow Growth		 0.00% -10.02% -64.44% -34.84% -113.12% -118.48% -13.27% 25.32% 23.91% -15.93%
Free Cash Flow Firm Growth		 0.00% 0.00% -255.11% -21.30% 130.88% -2,325.16% -16.49% 17.86% 38.88% 2.53%
Invested Capital Growth		 0.00% 0.00% 86.06% -98.31% -3,740.42% 36.99% 37.28% 53.87% 9.83% -195.06%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% 0.00% -16.27% -28.02% -21.76% 5.84% 5.16% 9.67% -5.81%
EBIT Q/Q Growth		 0.00% 0.00% 0.00% -15.67% -29.36% -20.89% 5.46% 3.50% 8.40% -5.04%
NOPAT Q/Q Growth		 0.00% 0.00% 0.00% -16.12% -29.10% -20.92% 5.27% 3.71% 8.43% -5.05%
Net Income Q/Q Growth		 0.00% 0.00% 0.00% -2.06% -30.32% -21.13% 6.37% 4.03% 8.04% -5.81%
EPS Q/Q Growth		 0.00% 0.00% 0.00% -635.29% -25.43% -18.62% 6.58% 4.05% 8.47% -5.11%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% -13.46% -8.16% -23.23% -21.31% 1.88% 12.90% 1.82% -7.35%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00% -57.52% -25.86% 1.09% -0.44% 23.53% -7.52%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00% -208.65% -9.68% 6.50% 26.09% 54.39% -42.36% -8.55%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 52.26% 66.48% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 100.04% 199.62% 200.69% 96.81% 97.84% 99.91% 97.93% 93.97% 94.05% 98.07%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 0.00% 149.22% -121.69% -21.92% -22.07% -35.04% -60.72% -74.22% -84.70% -149.49%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 0.00% 547.90% -32.33% -21.92% -22.07% -35.04% -60.72% -74.22% -84.70% -149.49%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 40.64% -47.73% -13.71% -15.46% -40.25% -76.54% 0.00% -117.25% 0.00%
Net Operating Profit after Tax (NOPAT)		 -12 -18 -18 -34 -95 -187 -239 -194 -131 -164
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 0.00% 236.25% -57.65% -5.93% -5.75% -9.42% -15.67% -17.36% -20.02% -34.87%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - -54.79% -73.04% -87.03% -104.25%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -17 -27 -31 -49 -136 -267 -341 -277 -187 -234
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -17 -25 -25 -48 -132 -258 -331 -252 -161 -208
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 3.01 7.72 7.65 6.61 0.86 0.60 3.48 9.42
Price to Tangible Book Value (P/TBV)		 0.00 0.00 3.01 7.72 7.65 6.61 0.86 0.60 3.48 9.42
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 550.30 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.00 -0.53 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 -0.53 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 0.00 -0.46 -1.17 -1.01 -1.09 -1.12 -1.10 -1.09 -1.09 -1.23
Leverage Ratio		 0.00 -0.17 1.40 1.04 1.18 1.29 1.43 1.63 1.96 2.23
Compound Leverage Factor		 0.00 -0.35 2.81 1.01 1.16 1.29 1.40 1.53 1.84 2.19
Debt to Total Capital		 0.00% -112.74% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% -112.74% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% -568.38% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 0.00% 781.11% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 -0.40 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 -0.34 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 -0.40 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 -0.56 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 -0.48 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 -0.56 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 0.00 -57.50 27.61 118.47 19.37 9.97 -1.81 -4.21 -5.17 -3.25
Noncontrolling Interest Sharing Ratio		 0.00% -267.17% 73.43% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 0.00 0.17 18.74 28.97 30.93 11.36 9.26 6.93 6.72 4.72
Quick Ratio		 0.00 0.15 18.29 28.73 30.84 11.31 9.12 6.84 6.57 4.61
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -7.67 -27 -33 10 -227 -264 -217 -133 -129
Operating Cash Flow to CapEx		 -2,081.32% -8,447.37% -37,219.23% -8,957.89% -2,187.41% -1,070.16% -557.68% -372.87% -31,285.07% -26,879.05%
Free Cash Flow to Firm to Interest Expense		 0.00 -6.47 -4.93 -4,129.50 408.00 -4,829.12 -14,688.29 -16,704.98 0.00 0.00
Operating Cash Flow to Interest Expense		 -2,674.50 -14.90 -5.26 -4,893.25 -3,337.12 -3,878.09 -11,469.94 -11,860.23 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 -2,803.00 -15.08 -5.27 -4,947.88 -3,489.68 -4,240.47 -13,526.67 -15,041.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 0.00 -10 -1.42 -2.82 -108 -68 -43 -20 -18 -52
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.00 -10 8.77 -1.40 -105 40 25 23 1.94 -35
Enterprise Value (EV)		 0.00 149 173 2,318 5,613 3,653 -104 -126 356 1,273
Market Capitalization		 90 90 261 2,666 6,582 4,385 375 160 524 1,483
Book Value per Share		 $0.00 ($9.15) $2.36 $9.32 $19.21 $12.83 $8.34 $5.07 $2.86 $2.97
Tangible Book Value per Share		 $0.00 ($9.15) $2.36 $9.32 $19.21 $12.83 $8.34 $5.07 $2.86 $2.97
Total Capital		 0.00 -8.80 87 345 861 663 436 266 150 157
Total Debt		 0.00 9.92 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 9.92 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 0.00 8.53 -88 -348 -969 -732 -479 -286 -168 -210
Capital Expenditures (CapEx)		 0.77 0.21 0.08 0.44 3.81 17 37 41 0.38 0.51
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 -8.96 -2.63 -8.96 -28 -61 -45 -38 -22 -41
Debt-free Net Working Capital (DFNWC)		 0.00 -7.56 86 328 941 670 434 248 146 169
Net Working Capital (NWC)		 0.00 -7.56 86 328 941 670 434 248 146 169
Net Nonoperating Expense (NNE)		 5.13 10 23 13 38 80 95 66 45 66
Net Nonoperating Obligations (NNO)		 0.00 8.53 -88 -348 -969 -732 -479 -286 -168 -210
Total Depreciation and Amortization (D&A)		 0.26 1.71 5.97 0.67 4.21 8.79 9.99 25 27 26
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 ($2.77) ($1.25) ($2.91) ($5.16) ($6.39) ($4.97) ($3.35) ($4.32)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 36.91M 44.42M 51.16M 51.93M 52.25M 52.41M 52.58M 53.21M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 ($2.77) ($1.25) ($2.91) ($5.16) ($6.39) ($4.97) ($3.35) ($4.32)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 36.91M 44.42M 51.16M 51.93M 52.25M 52.41M 52.58M 53.21M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 ($2.77) ($1.25) ($2.91) ($5.16) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 14.98M 37.85M 45.74M 51.79M 52.34M 52.51M 52.75M 61.85M
Normalized Net Operating Profit after Tax (NOPAT)		 -12 -18 -18 -34 -95 -187 -239 -194 -131 -164
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 -2,854.33 -22.60 -5.63 -6,115.63 -5,441.48 -5,685.98 -18,937.56 -21,323.92 0.00 0.00
NOPAT to Interest Expense		 -2,000.95 -15.08 -3.35 -4,304.13 -3,808.20 -3,977.36 -13,275.85 -14,932.67 0.00 0.00
EBIT Less CapEx to Interest Expense		 -2,982.83 -22.78 -5.64 -6,170.25 -5,594.04 -6,048.36 -20,994.28 -24,504.69 0.00 0.00
NOPAT Less CapEx to Interest Expense		 -2,129.45 -15.25 -3.36 -4,358.75 -3,960.76 -4,339.74 -15,332.57 -18,113.44 0.00 0.00
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -0.02% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Kodiak Sciences

This table displays calculated financial ratios and metrics derived from Kodiak Sciences' official financial filings.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
DEI Shares Outstanding		 52,472,291.00 52,508,602.00 52,534,947.00 52,614,729.00 - 52,748,343.00 52,763,541.00 52,821,689.00 53,048,428.00 61,847,870.00 62,578,441.00
DEI Adjusted Shares Outstanding		 52,472,291.00 52,508,602.00 52,534,947.00 52,614,729.00 - 52,748,343.00 52,763,541.00 52,821,689.00 53,048,428.00 61,847,870.00 62,578,441.00
DEI Earnings Per Adjusted Shares Outstanding		 -1.13 -0.82 -0.86 -0.84 - -1.09 -1.03 -1.16 -1.07 -0.94 -1.05
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 19.45% 42.61% 47.30% 15.99% 30.30% -31.67% -18.42% -39.73% -28.89% -2.15% -23.86%
EBIT Growth		 13.68% 37.64% 43.36% 14.45% 27.09% -27.31% -15.57% -33.69% -24.35% -1.25% -20.42%
NOPAT Growth		 14.44% 38.28% 43.44% 14.44% 27.13% -28.27% -15.69% -33.71% -24.41% -1.19% -20.41%
Net Income Growth		 15.52% 39.19% 43.74% 12.12% 25.89% -33.51% -20.38% -39.85% -28.64% -1.21% -20.86%
EPS Growth		 15.56% 39.26% 43.79% 11.58% 27.19% -32.93% -19.77% -38.10% -25.30% 13.76% -1.94%
Operating Cash Flow Growth		 41.46% 16.14% 36.86% 35.43% 6.73% 26.57% -30.88% -55.42% -30.95% -37.60% -33.35%
Free Cash Flow Firm Growth		 12.77% 42.72% 19.82% -20.15% 49.16% 68.68% 85.95% 87.71% 83.88% 26.45% -63.43%
Invested Capital Growth		 53.87% 83.46% 88.26% 71.11% 9.83% -502.73% -617.84% -286.95% -195.06% -101.44% -91.31%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -19.31% 29.96% -4.14% 3.45% 1.02% -32.32% 6.34% -13.91% 8.70% -4.87% -13.56%
EBIT Q/Q Growth		 -16.27% 26.84% -3.62% 2.94% 0.90% -27.75% 5.94% -12.28% 7.83% -4.01% -11.87%
NOPAT Q/Q Growth		 -16.28% 27.33% -4.19% 2.82% 0.97% -27.92% 6.03% -12.33% 7.86% -4.05% -11.81%
Net Income Q/Q Growth		 -19.02% 27.69% -4.83% 2.60% -0.36% -30.28% 5.48% -13.15% 7.68% -2.51% -12.87%
EPS Q/Q Growth		 -20.00% 28.07% -4.88% 2.33% 1.19% -31.33% 5.50% -12.62% 10.34% 9.62% -11.70%
Operating Cash Flow Q/Q Growth		 1.60% -22.83% 33.10% 20.14% -42.13% 3.30% -19.25% 5.17% -19.76% -1.60% -15.57%
Free Cash Flow Firm Q/Q Growth		 -27.74% 16.75% -23.08% 8.20% 45.95% 48.72% 44.79% 19.65% 29.13% -133.95% -22.68%
Invested Capital Q/Q Growth		 54.39% 76.02% 0.23% -164.76% -42.36% -60.29% -18.82% -42.72% -8.55% -9.43% -12.85%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 93.85% 92.77% 93.85% 94.19% 95.39% 97.29% 97.77% 98.53% 98.68% 97.26% 98.12%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -74.22% -73.45% -71.50% -78.57% -84.70% -108.92% -140.33% -207.92% -149.49% -208.80% -368.37%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -74.22% -73.45% -71.50% -78.57% -84.70% -108.92% -140.33% -207.92% -149.49% -208.80% -368.37%
Return on Equity Simple (ROE_SIMPLE)		 0.00% -96.50% 0.00% 0.00% 0.00% -175.14% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -44 -32 -34 -33 -32 -41 -39 -44 -40 -42 -47
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -3.96% -3.24% -3.86% -4.16% -5.19% -8.41% -9.56% -13.20% -8.74% -10.63% -16.39%
Return On Investment Capital (ROIC_SIMPLE)		 -16.69% -13.37% -15.66% -17.61% -21.51% -37.99% -55.28% -184.22% -25.55% -37.33% -76.58%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -63 -46 -48 -47 -46 -59 -56 -62 -57 -60 -67
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -57 -40 -41 -40 -40 -52 -49 -56 -51 -53 -61
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.60 1.15 0.58 0.74 3.48 1.36 2.80 36.50 9.42 21.03 39.91
Price to Tangible Book Value (P/TBV)		 0.60 1.15 0.58 0.74 3.48 1.36 2.80 36.50 9.42 21.03 39.91
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.09 -1.05 -1.08 -1.11 -1.09 -1.10 -1.14 -1.29 -1.23 -1.39 -1.75
Leverage Ratio		 1.63 1.70 1.79 1.89 1.96 2.09 2.31 2.83 2.23 2.73 3.91
Compound Leverage Factor		 1.53 1.57 1.68 1.78 1.87 2.04 2.26 2.78 2.20 2.66 3.84
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 -2.73 -2.72 -3.72 -4.22 -3.78 -6.25 -7.58 -7.73 -1.59 -0.25 -2.19
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 6.93 10.12 10.59 8.42 6.72 4.62 3.48 1.78 4.72 3.54 2.49
Quick Ratio		 6.84 9.89 10.34 8.22 6.57 4.50 3.36 1.70 4.61 3.42 2.39
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -67 -56 -69 -63 -34 -18 -9.70 -7.79 -5.52 -13 -16
Operating Cash Flow to CapEx		 -117.30% -180,000.00% -54,067.35% -11,753.33% -24,250.00% -10,769.26% -26,069.92% -54,800.00% -91,576.74% -4,247.24% -13,135.80%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -20 -4.73 -4.72 -12 -18 -29 -34 -48 -52 -57 -65
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 23 24 35 31 1.94 -24 -29 -36 -35 -29 -31
Enterprise Value (EV)		 -126 30 -96 -61 356 9.11 93 793 1,273 2,188 2,312
Market Capitalization		 160 276 123 137 524 148 197 865 1,483 2,358 2,438
Book Value per Share		 $5.07 $4.59 $4.08 $3.52 $2.86 $2.06 $1.33 $0.45 $2.97 $2.11 $0.98
Tangible Book Value per Share		 $5.07 $4.59 $4.08 $3.52 $2.86 $2.06 $1.33 $0.45 $2.97 $2.11 $0.98
Total Capital		 266 241 215 185 150 109 70 24 157 112 61
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -286 -246 -219 -198 -168 -139 -104 -72 -210 -170 -126
Capital Expenditures (CapEx)		 27 0.02 0.05 0.18 0.12 0.27 0.13 0.06 0.04 0.94 0.35
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -38 -19 -16 -19 -22 -27 -27 -39 -41 -44 -47
Debt-free Net Working Capital (DFNWC)		 248 227 203 178 146 112 77 33 169 126 79
Net Working Capital (NWC)		 248 227 203 178 146 112 77 33 169 126 79
Net Nonoperating Expense (NNE)		 15 11 12 11 12 16 15 18 17 16 19
Net Nonoperating Obligations (NNO)		 -286 -246 -219 -198 -168 -137 -104 -72 -210 -170 -126
Total Depreciation and Amortization (D&A)		 6.66 6.65 6.68 6.70 6.68 6.73 6.54 6.54 6.52 6.34 6.19
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($1.14) ($0.82) ($0.86) ($0.84) ($0.83) ($1.09) ($1.03) ($1.16) ($1.04) ($0.94) ($1.05)
Adjusted Weighted Average Basic Shares Outstanding		 52.41M 52.51M 52.55M 52.62M 52.58M 52.75M 52.78M 52.86M 53.21M 61.86M 62.63M
Adjusted Diluted Earnings per Share		 ($1.14) ($0.82) ($0.86) ($0.84) ($0.83) ($1.09) ($1.03) ($1.16) ($1.04) ($0.94) ($1.05)
Adjusted Weighted Average Diluted Shares Outstanding		 52.41M 52.51M 52.55M 52.62M 52.58M 52.75M 52.78M 52.86M 53.21M 61.86M 62.63M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 52.51M 52.53M 52.61M 52.62M 52.75M 52.76M 52.82M 53.05M 61.85M 62.58M 62.85M
Normalized Net Operating Profit after Tax (NOPAT)		 -44 -32 -34 -33 -32 -41 -39 -44 -40 -42 -47
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Kodiak Sciences (NASDAQ: KOD) remains a development-stage biotechnology company with no reported revenue. Revenue has been listed at $0 in every income statement period provided, leaving the company dependent on cash reserves, investment income and financing while it funds its pipeline.

The latest quarter showed continued financial pressure. In Q2 2026, Kodiak reported a $65.6 million net loss, compared with a $58.2 million loss in Q1 2026 and a $45.1 million loss in Q2 2024. Total operating expenses rose to $66.8 million from $55.5 million two years earlier, driven primarily by research and development spending of $56.1 million. Operating cash flow was negative $46.2 million in Q2 2026, worsening from negative $26.5 million in Q2 2024.

Liquidity has declined substantially over the longer term. Cash and equivalents fell to $125.9 million at June 30, 2026, from $345.7 million at September 30, 2023 and $219.2 million at June 30, 2024. At the Q2 2026 operating cash burn rate, the reported cash balance represents roughly 2.7 quarters of coverage before considering changes in spending, investment income or additional financing. The company did raise $173.1 million through common-stock issuance in Q4 2025, but that financing increased shareholder dilution.

There are some mitigating factors. Kodiak’s current assets of $131.4 million exceeded current liabilities of $52.8 million at the end of Q2 2026, and investing cash outflows remained modest. However, total equity declined from $112.1 million in Q1 2026 to $61.1 million in Q2 2026, while retained earnings remained deeply negative at approximately $1.68 billion. Investors should focus on clinical and regulatory progress, future financing needs and whether research spending can ultimately produce a commercial product.

  • Current liquidity remains above near-term obligations: current assets of $131.4 million were approximately 2.5 times current liabilities of $52.8 million at June 30, 2026.
  • Capital expenditures are limited: Q2 2026 purchases of property, plant and equipment were only $352,000, reducing the amount of cash committed to infrastructure.
  • SG&A has generally declined: selling, general and administrative expense fell to $10.8 million in Q2 2026 from $15.5 million in Q2 2024 and $16.7 million in Q3 2023.
  • Recent financing temporarily strengthened liquidity: the company raised $173.1 million through common-equity issuance in Q4 2025, helping fund operations into 2026.
  • Investment income provides a partial offset: interest and investment income was $1.3 million in Q2 2026, but this is considerably smaller than the $3.4 million reported in Q1 2024 and will likely decline as cash reserves shrink.
  • Research spending remains the primary use of capital: R&D expense was $56.1 million in Q2 2026, or roughly 84% of total operating expenses, reflecting continued pipeline investment but also a high dependence on development success.
  • No revenue has been reported: Kodiak recorded zero revenue and zero gross profit in each income statement period provided, so the business has not yet demonstrated commercial self-funding.
  • Losses and operating cash burn are worsening: the Q2 2026 net loss of $65.6 million and operating cash outflow of $46.2 million were both higher than in Q2 2024.
  • Cash reserves are declining: cash fell by $43.6 million during Q2 2026, following a $40.3 million decrease in Q1, despite modest financing inflows.
  • Shareholder dilution is a material risk: weighted-average basic shares increased to 62.6 million in Q2 2026 from 52.6 million in Q2 2024, while the company has relied on equity issuance to fund operations.
10/16/26 09:31 AM ETAI Generated. May Contain Errors.

Kodiak Sciences Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Kodiak Sciences' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Kodiak Sciences' net income appears to be on a downward trend, with a most recent value of -$229.97 million in 2025, falling from -$17.13 million in 2016. The previous period was -$176.21 million in 2024. See where experts think Kodiak Sciences is headed by visiting Kodiak Sciences' forecast page.

Kodiak Sciences' total operating income in 2025 was -$234.39 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $234.39 million

Over the last 9 years, Kodiak Sciences' total revenue changed from $0.00 in 2016 to $0.00 in 2025, a change of 0.0%.

In the past 12 quarters, Kodiak Sciences' cash and equivalents has ranged from $72.04 million in Q3 2025 to $378.67 million in Q2 2023, and is currently $125.90 million as of their latest financial filing in Q2 2026.

Kodiak Sciences had total debt of $0.00 at the end of 2025, compared with none in 2024, and none in 2016.

Over the last 9 years, Kodiak Sciences' book value per share changed from 0.00 in 2016 to 2.97 in 2025, a change of 296.7%.


Related Companies

Financial statements for NASDAQ:KOD last updated on 8/13/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
My next big call (under $1)
Bitcoin is trading near $80,000. For your Bitcoin position to double from here, roughly $1.5 trillion in new m...
Crypto 101 Media | Sponsoredtc pixel
Trump’s issues shocking Executive Order on U.S. Dollar
Three days into his second term, President Trump signed Executive Order 14178 a move the press barely covered....
Banyan Hill Publishing | Sponsoredtc pixel
Your Social Security check is scheduled for a 22% cut
The U.S. now borrows money just to pay interest on money it already borrowed, a pattern economists call a debt...
American Alternative | Sponsoredtc pixel
Undiscovered Sub-$1 Gold-Silver Royalty Stock Takes Flight
A small-cap gold and silver royalty company is generating record revenue from producing mines, yet shares stil...
Digest Publishing | Sponsoredtc pixel
“The crisis that’s emerging now is just the tip of the iceberg,” says Dr. Martin D. Weiss, who has made shocking and accurate predictions for 55 years
Dr. Martin D. Weiss, who predicted the Dot-Com collapse and the failures of Fannie Mae, Bear Stearns, and Lehm...
Weiss Ratings | Sponsoredtc pixel
Stop picking AI winners. Start collecting every Thursday
One fund holds Nvidia, CrowdStrike, Palantir and other major AI names, and pays a 34% annualized distribution ...
Investors Alley | Sponsoredtc pixel
Bezos… DOOMED
A single FCC filing hints Elon Musk is planning his biggest project yet - bigger than Tesla, SpaceX, and X com...
Paradigm Press | Sponsoredtc pixel
Buffett's Final Warning: "The Dollar Is Going to Hell"
Do not buy another AI stock until you've seen the arithmetic below. Nvidia is worth about $5.5 trillion. Al...
Decentralized Masters | Sponsoredtc pixel